As far as we know, our study is the first randomized, double‐blind, placebo‐controlled trial that assessing the efficacy and safety of pentoxifylline as PDE inhibitor in alleviating the negative symptoms in chronic schizophrenia. Here, ALDH7A1 is linked to schizophrenia.